Closing the Pre-Seed at $925,000
Madeed, a Saudi Arabia-based healthtech startup, has closed its pre-seed round at $925,000. The latest tranche brings in three new investors and expands on the $400,000 initial close announced in January.
The company is building a membership-based preventive health platform focused on early disease risk detection through advanced biomarkers and laboratory testing. According to the company, the new capital will go toward product development and the expansion of clinical and lab partnerships, starting in Saudi Arabia.
Who Backed the Round
The latest tranche included SEEDRA Ventures, Unity Investment Partners, and Seen Growth. They join earlier backers including Vision Ventures, which led the January close, alongside Saudi angel investors Mashhoor Aldubayan, Mazen Aldarrab, and Abdulla Nadeem Elyas.
How the Platform Works
Madeed combines diagnostics, physician-led interpretation, and personalised intervention into a single subscription. Members reportedly receive advanced blood and biomarker testing, detailed health reports, and clinical reviews covering metabolic health, hormonal balance, cardiovascular risk, and inflammation.
A defining feature is the company's customised daily supplement packs, which are designed individually based on each member's lab results. Madeed positions the product as a data-driven alternative to the generic wellness supplements widely sold across the region.
From Span Health to Riyadh
Madeed was founded in 2025 by Adam Bataineh, a medical doctor who previously co-founded US-based Span Health, a preventive health company that was later acquired by Eight Sleep. He is bringing a similar playbook to the Gulf at a moment when Saudi Arabia is investing heavily in healthcare under Vision 2030.
The startup reportedly attracted 150 subscribers during its pilot phase, which the company described as an early signal of demand ahead of a wider launch.
What's Driving the Demand
Saudi Arabia is one of the fastest-moving healthcare markets in the region. Government programmes have pushed for greater private sector participation, more digital infrastructure, and longer healthy life expectancy as a national target. Preventive and longevity-focused products fit directly into that agenda.
For Madeed, the early traction and second close give it runway to deepen lab and clinical partnerships before pursuing wider regional expansion. The company has reportedly signalled plans to move beyond Saudi Arabia after consolidating its base in the kingdom.
